Abstract
(35%) and photosensitivity reactions (25%), grade 1 or 2 side effects as per the Common Terminology Criteria for Adverse Events (CTCAE). Elevated liver enzymes were documented in close to 10% of treated patients and no prolongation of the QTc interval, cardiac arrhythmias, keratoacanthoma and squamous cell carcinoma were reported. Dosing’s modification has been required in three patients: two patients have discontinued the treatment and they have been resumed at 720 mg/bid while one patient have been resumed at 480 mg/bid. Nobody needed to stop the treatment due to unacceptable toxicities. Conclusions According to the findings available in literature, inhibition of BRAF improves clinical outcome in patients with the BRAF V600E mutation. Vemurafenib was well tolerated and adverse event profiles were similar to those reported in literature.
Highlights
Metastatic melanoma has a poor prognosis, and 5-year survival is 65% with regional stage disease and 15% with distant stage disease
Malignant melanoma is not a singular, homogeneous disease but rather a mixture of subtypes characterized by specific mutations
Tumours with BRAF mutations respond to BRAF kinase inhibitor vemurafenib, that was approved by US FDA in 2011 and EMA in 2012 for therapy of patients with advanced melanoma, harboring mutation in BRAF V600E gene
Summary
Metastatic melanoma has a poor prognosis, and 5-year survival is 65% with regional stage disease and 15% with distant stage disease. Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas From Melanoma Bridge Meeting 2014 Naples, Italy. Background Metastatic melanoma has a poor prognosis, and 5-year survival is 65% with regional stage disease and 15% with distant stage disease. Chemotherapy has limited success in metastatic melanoma, with a median overall survival of 8 months.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
